TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02974634

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ostomy self management training
Description: Ostomy Self management Training group in which subject will learn using pouches and equipment, skin care, ostomy complications, nutritional needs, Impact on feelings, clothing changes, social relationships, being prepared for emergencies, Intimacy and sexuality, communication skills, tips for travelling and physical activity recommendations

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Ostomy self management training
Description: Ostomy Self management Training group in which subject will learn using pouches and equipment, skin care, ostomy complications, nutritional needs, Impact on feelings, clothing changes, social relationships, being prepared for emergencies, Intimacy and sexuality, communication skills, tips for travelling and physical activity recommendations
Study: NCT01935947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given PO
Study: NCT01876394

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chia Oil
Description: Shake with 50 g Chia oil

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chia Oil
Description: Shake with 50 g Chia oil

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Butter
Description: Shake with 50 g Butter

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Butter
Description: Shake with 50 g Butter

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Butter
Description: Shake with 50 g Butter

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Butter
Description: Shake with 50 g Butter

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Butter
Description: Shake with 50 g Butter
Study: NCT04237402

Intervention type: OTHER
Group type: OTHER
Intervention: Hair follicles sampling
Description: The hair follicles will be collected by strand of 5 to 6 hairs approximately in the scalp (centro-parietal part), in order to obtain 20 follicles with epithelial sheath.
Study: NCT04134585

Intervention type: OTHER
Intervention: semi-structured interviews
Description: Semi-structured interviews will be performed to determine representations of physical activity, reluctance/motivation to participate in physical activity sessions and facilitators who can help them overcome these barriers.
Study: NCT03587480

Intervention type: PROCEDURE
Group type: OTHER
Intervention: TME+LLND
Description: patients in TME+LLND group receive Lateral Lymph Node Dissection (LLND) after Total Mesorectal Excision(TME)

Intervention type: PROCEDURE
Group type: OTHER
Intervention: TME+nCRT
Description: patients in TME+nCRT group receive Neoadjuvant Chemo-radiotherapy (nCRT) before Total Mesorectal Excision(TME)
Study: NCT04822857

Intervention type: DIAGNOSTIC_TEST
Intervention: AMH
Description: The group was divided according to the level of Anti-Müllerian Hormone

Intervention type: DIAGNOSTIC_TEST
Intervention: AMH
Description: The group was divided according to the level of Anti-Müllerian Hormone
Study: NCT03529136

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UC-MSC
Description: Human umbilical cord mesenchymal stem cells have driven from Wharton's jelly and cultured with serum-free medium in Shandong Cell and tissue bank. All of the cells in this study within three passages. Before transfusion, the mesenchymal stem cells were subjected to quality control. The UC-MSC were stained with anti-CD90-FITC, Anti-CD44-FITC, Anti-CD34-FITC and anti-45-FITC.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UC-MSC
Description: Human umbilical cord mesenchymal stem cells have driven from Wharton's jelly and cultured with serum-free medium in Shandong Cell and tissue bank. All of the cells in this study within three passages. Before transfusion, the mesenchymal stem cells were subjected to quality control. The UC-MSC were stained with anti-CD90-FITC, Anti-CD44-FITC, Anti-CD34-FITC and anti-45-FITC.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UC-MSC
Description: Human umbilical cord mesenchymal stem cells have driven from Wharton's jelly and cultured with serum-free medium in Shandong Cell and tissue bank. All of the cells in this study within three passages. Before transfusion, the mesenchymal stem cells were subjected to quality control. The UC-MSC were stained with anti-CD90-FITC, Anti-CD44-FITC, Anti-CD34-FITC and anti-45-FITC.
Study: NCT00423618

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiotherapy
Description: radiotherapy as adjuvant treatment for adults with soft tissue sarcoma extremities

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: radiotherapy as adjuvant treatment for adults with soft tissue sarcoma extremities
Study: NCT02010437

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Tetradecyl Sulphate (STS)
Study: NCT02645006

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 3 session workshop
Description: The intervention group will attend a three session workshop, will learn to recognize their risk factors for fall, will be encouraged to adopt a healthy diet (vitamin D consumption), modify home hazards , and increase physical activity (a strength and balance program at home and a group walking route). After a monthly telephone follow-up they are invited to attend a recall session, were they realize the change in the strength and balance tests results.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: 1 session workshop
Description: The control group will attend a single workshop session summarizing the major points of prevention of falls ( risk factors of fall, healthy diet and vitamin D consumption, home hazards, physical activity). After a monthly telephone follow-up they are invited to attend the three session workshop for further prevention.
Study: NCT04147819

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2701439
Description: Intravenous (IV) injection on Day 1 of each cycle.The duration of each cycle will be 6 weeks (42 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2701439
Description: Intravenous (IV) injection on Day 1 of each cycle.The duration of each cycle will be 6 weeks (42 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2701439
Description: Intravenous (IV) injection on Day 1 of each cycle.The duration of each cycle will be 6 weeks (42 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2701439
Description: Intravenous (IV) injection on Day 1 of each cycle.The duration of each cycle will be 6 weeks (42 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2701439
Description: Intravenous (IV) injection on Day 1 of each cycle and 1 hour before the start of administration of BAY2701439. The duration of each cycle will be 6 weeks (42 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2701439
Description: Intravenous (IV) injection on Day 1 of each cycle and 1 hour before the start of administration of BAY2701439. The duration of each cycle will be 6 weeks (42 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2701439
Description: Intravenous (IV) injection on Day 1 of each cycle and 1 hour before the start of administration of BAY2701439. The duration of each cycle will be 6 weeks (42 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2701439
Description: Intravenous (IV) injection on Day 1 of each cycle and 1 hour before the start of administration of BAY2701439. The duration of each cycle will be 6 weeks (42 days).
Study: NCT04008537

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ring gantry kV-CBCT combined with linear accelerator
Description: Each imaging session will be less than one hour, and is expected to take no more than 15 minutes.
Study: NCT03978091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZACTAM
Description: A synthetic monobactam antibiotic originally isolated from Chromobacterium violaceum

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZACTAM
Description: A synthetic monobactam antibiotic originally isolated from Chromobacterium violaceum

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZACTAM
Description: A synthetic monobactam antibiotic originally isolated from Chromobacterium violaceum

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZACTAM
Description: A synthetic monobactam antibiotic originally isolated from Chromobacterium violaceum

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftazidime-Avibactam
Description: An antibacterial combination product containing ceftazidime and avibactam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftazidime-Avibactam
Description: An antibacterial combination product containing ceftazidime and avibactam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftazidime-Avibactam
Description: An antibacterial combination product containing ceftazidime and avibactam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftazidime-Avibactam
Description: An antibacterial combination product containing ceftazidime and avibactam
Study: NCT00650988

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryospray Ablation
Description: Liquid nitrogen spray with a cryospray catheter through an upper endoscope that enables the direct visualization of mucosal freeze (cryoburn) of the mucosa treated which avoids the need for direct tissue contact. Frozen state is defined as mucosa appearing white. Cryofreeze is preformed in cycles of 10 second sprays with a minimal thaw of 60 seconds each spray. This cycle is repeated 4 times in each area of treatment.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryospray Ablation
Description: Liquid nitrogen spray with a cryospray catheter through an upper endoscope that enables the direct visualization of mucosal freeze (cryoburn) of the mucosa treated which avoids the need for direct tissue contact. Frozen state is defined as mucosa appearing white. Cryofreeze is preformed in cycles of 10 second sprays with a minimal thaw of 60 seconds each spray. This cycle is repeated 4 times in each area of treatment.
Study: NCT00591331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spinosad (the active ingredient in NatrOVA)
Description: This is a patch test in which the test material is applied to the patch and the patch applied to the skin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spinosad (the active ingredient in NatrOVA)
Description: This is a patch test in which the test material is applied to the patch and the patch applied to the skin.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT01387763

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PegIntron
Description: PegIntron, prefilled syringe 50 micrograms/0.5 ml. 30 micrograms subcutaneously once weekly.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegasys
Description: Pegasys, prefilled syringe 180 micrograms/0.5 ml 45 micrograms subcutaneously once weekly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PegIntron
Description: PegIntron, prefilled syringe 50 micrograms/0.5 ml. 30 micrograms subcutaneously once weekly.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegasys
Description: Pegasys, prefilled syringe 180 micrograms/0.5 ml 45 micrograms subcutaneously once weekly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrea
Description: Capsule Hydrea 500-2000 mg orally QD or BID
Study: NCT03878888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exparel 266 MG Per 20 ML Injection
Description: patients receive Exparel in bilateral TAP blocks for open abdomen surgery
Study: NCT04636593

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Almonertinib
Description: All enrolled patients underwent positioning CT scans before the initial treatment, a radiotherapy plan was made for each patient, and the lung V20 of each patient was calculated. Patients with lung V20 ≥ 28% were enrolled in group A: Almonertinib induction therapy was given for 2 months firstly, followed by Almonertinib combined with radiotherapy; patients with lung V20\<28% were enrolled in group B: Almonertinib was synchronized with radiotherapy initially.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Almonertinib
Description: All enrolled patients underwent positioning CT scans before the initial treatment, a radiotherapy plan was made for each patient, and the lung V20 of each patient was calculated. Patients with lung V20 ≥ 28% were enrolled in group A: Almonertinib induction therapy was given for 2 months firstly, followed by Almonertinib combined with radiotherapy; patients with lung V20\<28% were enrolled in group B: Almonertinib was synchronized with radiotherapy initially.
Study: NCT01708499

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ulthera System Treatment
Description: Focused ultrasound energy delivered below the surface of the skin
Study: NCT03339024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intranasal oxytocin spray
Description: 6 insufflations (24 IU of oxytocin total) given twice daily, day 1-3. 2 insufflations (8 IU of oxytocin total) as needed, max thrice daily, day 3-30 Day 30 - 12 months: No further oxytocin treatment, i.e. treatment-as-usual.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: intranasal spray without oxytocin
Description: 6 insufflations (24 IU of placebo total) given twice daily, day 1-3. 2 insufflations (8 IU of placebo total) as needed, max thrice daily, day 3-30 Day 30 - 12 months: No further oxytocin treatment, i.e. treatment-as-usual.
Study: NCT02589340

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buspirone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar Pill
Study: NCT02972801

Intervention type: PROCEDURE
Intervention: Testicular biopsy
Description: Testicular biopsy is performed to obtain testicular tissue for cryopreservation
Study: NCT00638482

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Description: Hydrochlorothiazide
Study: NCT02916589

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Diet

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Diet
Study: NCT03880734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: ingredients-Cholecalciferol (40,000 IU),Microcrystalline Cellulose (58.1 gm),Butylated Hydroxy Toluene (0.2 mg),Magnesium Stearate (3 mg),Gelatin Capsule Shell (1 mg)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo oral capsule
Description: ingredients- Microcrystalline Cellulose (303.8 gm),Butylated Hydroxy Toluene (0.2 mg),Magnesium Stearate (3 mg),Gelatin Capsule Shell (1 mg)
Study: NCT04061265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Articaine 4%/Epi 1:100000 Inj Cart 1.7Ml
Description: Local anesthetic agent

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine hydrochloride 2% and epinephrine 1:100000
Description: Local anesthetic agent
Study: NCT01935947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entinostat
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entinostat
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan Hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed Disodium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed Disodium
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed Disodium
Description: Given IV
Study: NCT02896205

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: Subjects will be given oral Mycophenolate Mofetil starting at 500mg twice a day and increased gradually to a target dose of 2gram per day for 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will be given matching placebo for 6 months
Study: NCT02428426

Intervention type: OTHER
Intervention: endomicroscopy, targeted biopsy and 16s rRNA gene sequencing

Intervention type: OTHER
Intervention: endomicroscopy, targeted biopsy and 16s rRNA gene sequencing
Study: NCT00603681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyethylene glycol 4000
Description: powder for oral solution 12 g of PEG once a day, twice a day or once every other day for 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polyethylene glycol 4000 with electrolytes
Description: granules for oral solution 12 g of PEG once a day, twice a day or once every other day for 4 weeks
Study: NCT03807089

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Pediatric Colonoscope

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Short-Turn Radius Colonoscope
Study: NCT03289754

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iPoly XE tibial insert with ConforMIS iTotal KRS
Description: The implants are constructed to conform to the surface of the patient's femoral condyle and proximal tibia, replacing the damaged cartilage with a smooth articulating surface. The femoral component and tibial tray are manufactured from cobalt chromium molybdenum alloy. The tibial insert and patellar component are manufactured from ultra-high molecular weight polyethylene.
Study: NCT02328872

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Molecular testing for HPV
Description: Molecular testing for HPV with a test allowing partial genotyping for separate identification of types 16/18 from cervical samples. The technology used in this trial will be approved by the Therapeutic Goods Administration (TGA) Australia. It will identify the major HPV oncogenic genotypes in a pool and separately identify HPV 16 and 18. It will also satisfy performance criteria for relative sensitivity and specificity compared to Hybrid Capture 2 (HC2 ) as articulated by Meijer et al, 2009, Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Liquid Based Cytology
Description: The liquid based cytology (LBC) used in this trial will be will be approved by the Therapeutic Goods Administration (TGA) Australia for LBC and appropriately validated and (TGA approved) to perform human papillomavirus testing from a cytology sample.
Study: NCT01603654

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium picosulphate magnesium citrate
Description: Use of the product in colon cleansing before colonoscopy. Two sachets each containing 10 mg of sodium picosulfate, 3.5 g magnesium oxide and 12.0 g citric acid. The 2 doses are taken diluted in a glass water.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: low-volume PEG -ascorbic acid
Description: THe product is used as colon cleanser before colonoscopy. It is supplied as a powder for oral use, to be reconstituted with 2 L of water and drunk as a solution. It consists of 100.0 g macrogol 3350 plus electrolytes (7.5 g sodium sulphate, 2.7 g sodium chloride, 1.0 g potassium chloride) and 4.7 g ascorbic acid.
Study: NCT04556253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK104
Description: Subjects will receive AK104 by intravenous administration.
Study: NCT00364325

Intervention type: OTHER
Intervention: Acute Decompensated Heart Failure
Description: Standard of Care
Study: NCT03083509

Intervention type: OTHER
Group type: OTHER
Intervention: Resistance exercise weight training session
Description: A resistance exercise session was performed. Following a warm-up that consisted of five-minutes cycling at a self-selected intensity, as well as three progressive lifts at 50, 75, and 90% 6 rep max (RM), participants performed four sets of six repetitions at 100% of 6RM (as determined by the maximal weight lifted during the maximal strength assessment) of the following lifts; back squat, front squat, good mornings, and Bulgarian split-squat. Two minutes rest was afforded between sets and exercises.
Study: NCT03181191

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oral glucose tolerance test
Description: Oral glucose tolerance test and biopsies
Study: NCT03083509

Intervention type: OTHER
Group type: OTHER
Intervention: High-Intensity stochastic cycling session
Description: A high-intensity stochastic cycling session was performed. The cycling protocol was performed using a magnetically-braked cycle ergometer (Velotron, RacerMate). Following a 10 minute standardised warm-up including 3 × 3s sprints, participants completed a simulated road-race, consisting of sprints of varied length, differing work to rest ratios and short time-trials.
Study: NCT03181191

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oral glucose tolerance test
Description: Oral glucose tolerance test and biopsies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oral glucose tolerance test
Description: Oral glucose tolerance test and biopsies
Study: NCT01370148

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: conivaptan hydrochloride
Description: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: conivaptan hydrochloride
Description: Intravenous
Study: NCT03982160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-Arginine
Description: Arginine Hydrochloride 60% concentration injection 15 g in 25 mL, contains arginine hydrochloride 600 mg/mL in water for injections to 25 mL.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline